Literature DB >> 8829657

Fumarylacetoacetase mutations in tyrosinaemia type I.

H Rootwelt1, K Høie, R Berger, E A Kvittingen.   

Abstract

Sixty-two hereditary tyrosinaemia type I (HT1) patients of various ethnic origins were classified clinically into acute, chronic, or intermediate phenotypes and screened for the 14 published causal mutations in the fumarylacetoacetase (FAH) gene. Restriction analysis of PCR amplified genomic DNA identified 74% of the mutated alleles. IVS12 + 5G --> A, predominant in the French Canadian HT1 patients, was the most common mutation found in 32 alleles in patients from Europe, Pakistan, Turkey, and the United States. IVS6-1G --> T, encountered in 14 alleles, was common in Central and Western Europe. There was an apparent "Scandinavian" 1009G --> A combined splice and missense mutation (12 alleles), a "Pakistani" 192G --> T splice mutation (11 alleles), a "Turkish" D233V mutation (6 alleles), and a "Finnish" or northern European W262X mutation (7 alleles). The remaining mutations were rare. Some of the mutations seem to predispose for acute and other for more chronic forms of HT1, but in our material no clearcut genotype phenotype correlation could be established.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8829657     DOI: 10.1002/(SICI)1098-1004(1996)7:3<239::AID-HUMU8>3.0.CO;2-5

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential.

Authors:  Giancarlo la Marca; Sabrina Malvagia; Elisabetta Pasquini; Catia Cavicchi; Amelia Morrone; Federica Ciani; Silvia Funghini; Fabio Villanelli; Enrico Zammarchi; Renzo Guerrini
Journal:  JIMD Rep       Date:  2011-06-22

2.  Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease.

Authors:  A Dursun; R K Ozgül; S Sivri; A Tokatlı; A Güzel; L Mesci; M Kılıç; D Aliefendioglu; F Ozçay; M Gündüz; T Coşkun
Journal:  JIMD Rep       Date:  2011-06-22

3.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

4.  A minor alternative transcript of the fumarylacetoacetate hydrolase gene produces a protein despite being likely subjected to nonsense-mediated mRNA decay.

Authors:  Natacha Dreumont; Antonella Maresca; Jean-François Boisclair-Lachance; Anne Bergeron; Robert M Tanguay
Journal:  BMC Mol Biol       Date:  2005-01-07       Impact factor: 2.946

5.  Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate.

Authors:  Iratxe Macias; Ana Laín; Ganeko Bernardo-Seisdedos; David Gil; Esperanza Gonzalez; Juan M Falcon-Perez; Oscar Millet
Journal:  J Biol Chem       Date:  2019-07-12       Impact factor: 5.157

6.  Clinical and genetic characteristics of two patients with tyrosinemia type 1 in Slovenia - A novel fumarylacetoacetate hydrolase (FAH) intronic disease-causing variant.

Authors:  Jaka Sikonja; Jernej Brecelj; Mojca Zerjav Tansek; Barbka Repic Lampret; Ana Drole Torkar; Simona Klemencic; Neza Lipovec; Valentina Stefanova Kralj; Sara Bertok; Jernej Kovac; Barbara Faganel Kotnik; Marketa Tesarova; Ziga Iztok Remec; Marusa Debeljak; Tadej Battelino; Urh Groselj
Journal:  Mol Genet Metab Rep       Date:  2021-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.